Literature DB >> 3885981

Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril.

M A Creager, D P Faxon, D A Weiner, T J Ryan.   

Abstract

The contribution of the renin-angiotensin system to the cardiovascular response to exercise was studied in 12 patients with congestive heart failure. The haemodynamic effects of captopril were measured at rest and during supine bicycle exercise. After captopril administration, resting systemic vascular resistance fell by 26.6% and mean blood pressure by 16.7% and cardiac index increased by 19.7%. During exercise, captopril decreased systemic vascular resistance by 25.6% and mean blood pressure by 8.2% and increased cardiac index by 24.4%. Pulmonary wedge pressure fell by 25% at rest but was not altered by captopril during exercise. Pretreatment plasma renin activity increased from 13.4(16.0) ng/ml/hr (10.3(12.3) mmol/l/hr) at rest to 20.0(27.8) ng/ml/hr (15.4(21.4) mmol/l/hr) during exercise. Pretreatment plasma noradrenaline concentration increased from 659(433) pg/ml (39(25.6) nmol/l) at rest to 2622(1486) pg/ml during exercise (155(88) nmol/l). Captopril favourably alters systemic vascular resistance and cardiac index during exercise in patients with congestive heart failure. This may reflect inhibition of the increased activity of the renin-angiotensin system during exercise in these patients and a subsequent reduction in systemic vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3885981      PMCID: PMC481784          DOI: 10.1136/hrt.53.4.431

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  26 in total

1.  Peripheral venous and arteriolar responses to infusions of angiotensin in normal and hypertensive subjects.

Authors:  J E WOOD
Journal:  Circ Res       Date:  1961-05       Impact factor: 17.367

2.  Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure.

Authors:  R J Cody; A B Covit; G L Schaer; J H Laragh
Journal:  J Am Coll Cardiol       Date:  1983-04       Impact factor: 24.094

3.  Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study.

Authors:  B L Kramer; B M Massie; N Topic
Journal:  Circulation       Date:  1983-04       Impact factor: 29.690

4.  Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure.

Authors:  M A Creager; J L Halperin; D B Bernard; D P Faxon; C D Melidossian; H Gavras; T J Ryan
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

5.  Effect of renin-angiotensin system on limb circulation in normal subjects.

Authors:  M A Creager; D P Faxon; S M Rockwell; J C Melby; H Gavras; J D Coffman
Journal:  Am J Physiol       Date:  1984-02

6.  Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure.

Authors:  G S Francis; S R Goldsmith; S M Ziesche; J N Cohn
Journal:  Am J Cardiol       Date:  1982-04-01       Impact factor: 2.778

7.  Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure.

Authors:  J L Halperin; D P Faxon; M A Creager; T A Bass; C D Melidossian; H Gavras; T J Ryan
Journal:  Am J Cardiol       Date:  1982-11       Impact factor: 2.778

8.  Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy.

Authors:  D P Faxon; J L Halperin; M A Creager; H Gavras; E C Schick; T J Ryan
Journal:  Am Heart J       Date:  1981-05       Impact factor: 4.749

9.  Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations.

Authors:  L DiCarlo; K Chatterjee; W W Parmley; K Swedberg; B Atherton; D Curran; M Cucci
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094

10.  Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man.

Authors:  S L Swartz; G H Williams; N K Hollenberg; L Levine; R G Dluhy; T J Moore
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

View more
  5 in total

Review 1.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  Enalapril reduces the catecholamine response to exercise in patients with heart failure.

Authors:  B P McGrath; L F Arnolda
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  A randomized cross-over study of enalapril in congestive heart failure: haemodynamic and hormonal effects during rest and exercise.

Authors:  I P Mulligan; A G Fraser; V Tirlapur; M J Lewis; R G Newcombe; A H Henderson
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress.

Authors:  René R Wenzel; Anna Mitchell; Winfried Siffert; Sandra Bührmann; Thomas Philipp; Rafael F Schäfers
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.